The purpose of this study is to compare the effects of pravastatin and rosuvastatin on
coronary plaque characteristics in patients with stable angina pectoris.
Drug: pravastatin, rosuvastatin
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01325818
Ages eligible for Study
20 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Patients who have been diagnosed as stable angina pectoris, and successful percutaneous coronary intervention (PCI) were performed with intravascular ultrasound
(IVUS) and optical coherence tomography (OCT) guidance.
Patients having coronary plaques (≧ 500 µm in thickness or % plaque of 20% or more at
≧ 5 mm distal or proximal to the previously treated area in the same branch of coronary artery.
Patients with dyslipidemia as defined by any of the following criteria:
TC ≧ 220 mg/dL
LDL-C ≧ 140 mg/dL
Cholesterol-lowering treatment is allowed according to the investigator's judgment when LDL-C ≧ 100 mg/dL or TC ≧ 180mg/dL.
Patients who are under cholesterol-lowering treatment and LDL-C ≦ 120 mg/dL
Patients 20 years or older at the time of their consent.
Patients with written consent by their own volition after being provided sufficient explanation for their participation in this clinical trial.
Patients with bypass graft or in-stent restenosis at the site of PCI.
Patients who received PCI in the past on the lesion where the evaluation of coronary plaque volume is planned.
Patients who had plaques in a non-culprit site and might receive PCI during the treatment period.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.